Key result
The development of antianginal pharmacotherapy for chronic coronary insufficiency is primarily focused on improving the pharmacokinetic properties of already known drugs.
Why the study?
The evolution of antianginal pharmacotherapy has been driven by the ongoing search for key determinants of effective pharmacodynamics.
Recent developments in antianginal pharmacotherapy are primarily focused on improving the pharmacokinetic properties of existing medications.
May not hasten new antianginal classes; leaves open mechanistic innovation research.
The formation of antianginal pharmacotherapy has gone a long way, characterized by the search for the main factors of effective pharmacodynamics. The article presents an analysis of the use of drugs with different pharmacological properties in patients suffering from angina pectoris in a historical aspect, shows the evolution of researchers’ ideas about the mechanism of antianginal action, and gives a brief description of modern antianginal drugs. Analysis of the features of drug treatment of chronic coronary insufficiency with angina attacks gives reason to say that the development of pharmacology in this section of cardiology is in the direction of improvement, first of all, in the pharmacokinetic aspect of already known drugs.
No takes yet. Share an insight, caveat, or question.
Oleksii Korzh (2023) conducted a review in Angina pectoris. Antianginal pharmacotherapy was evaluated. The development of antianginal pharmacotherapy for chronic coronary insufficiency is primarily focused on improving the pharmacokinetic properties of already known drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: